## **Anthony Chalmers**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3231819/publications.pdf

Version: 2024-02-01

87 papers 4,988 citations

32 h-index 98798 67 g-index

93 all docs 93 docs citations

93 times ranked 8724 citing authors

#	Article	IF	CITATIONS
1	Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis. International Journal of Radiation Oncology Biology Physics, 2022, 112, 197-211.	0.8	13
2	Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma. Magnetic Resonance Imaging, 2022, 85, 121-127.	1.8	0
3	Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date. Seminars in Radiation Oncology, 2022, 32, 15-28.	2.2	8
4	Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors?. Neuro-Oncology Advances, 2022, 4, vdab190.	0.7	6
5	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. International Journal of Radiation Oncology Biology Physics, 2022, 112, 265-270.	0.8	1
6	Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 2022, 29, 2089-2104.	11.2	10
7	Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. CNS Oncology, 2022, 11, .	3.0	5
8	Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease. International Journal of Radiation Oncology Biology Physics, 2021, 109, 886-890.	0.8	13
9	Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease. Clinical Oncology, 2021, 33, e64-e68.	1.4	2
10	Loss of $TGF\hat{I}^2$ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Science Translational Medicine, 2021, 13, .	12.4	33
11	An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 2021, 6, 100653.	1.2	11
12	Radiobiology Summaries: DNA Damage and Repair. Clinical Oncology, 2021, 33, 275-278.	1.4	2
13	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. Journal of Thoracic Oncology, 2021, 16, 1705-1717.	1.1	10
14	Geriatric assessment of glioblastoma patients is feasible and may provide useful prognostic information. Neuro-Oncology Practice, 2020, 7, 176-184.	1.6	5
15	Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ. Molecular Cancer Therapeutics, 2020, 19, 575-589.	4.1	24
16	CTRad 10 Years On: From 10-point Plan to Top 10 Achievements. Clinical Oncology, 2020, 32, 9-12.	1.4	4
17	Mesothelioma Cells Depend on the Antiapoptotic Protein Bcl-xL for Survival and Are Sensitized to lonizing Radiation by BH3-Mimetics. International Journal of Radiation Oncology Biology Physics, 2020, 106, 867-877.	0.8	13
18	Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts. Scientific Reports, 2020, 10, 15361.	3.3	10

#	Article	IF	Citations
19	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 25, 61-66.	1.7	15
20	Cytotoxicity and Radiosensitizing Activity of the Fatty Acid Synthase Inhibitor C75 Is Enhanced by Blocking Fatty Acid Uptake in Prostate Cancer Cells. Advances in Radiation Oncology, 2020, 5, 994-1005.	1.2	19
21	Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. Neuro-Oncology Advances, 2020, 2, vdaa046.	0.7	7
22	Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 2020, 22, 1840-1850.	1.2	77
23	Multifaceted transforming growth factor-beta (TGF $\hat{I}^2$ ) signalling in glioblastoma. Cellular Signalling, 2020, 72, 109638.	3.6	23
24	Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: Application to an infiltrative brain tumour model. Journal of Neuroscience Methods, 2019, 326, 108372.	2.5	4
25	Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements. Scientific Reports, 2019, 9, 10837.	3.3	40
26	Pre-EDIT. Chest, 2019, 156, 1204-1213.	0.8	22
27	A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. Cancer Research, 2019, 79, 1226-1238.	0.9	26
28	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3
29	DNA Repair in Radiation Oncology. , 2019, , 1-16.		0
30	Patient-specific 3D-printed glioblastomas. Nature Biomedical Engineering, 2019, 3, 498-499.	22.5	14
31	An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?. CNS Oncology, 2019, 8, CNS47.	3.0	3
32	Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature, 2019, 573, 532-538.	27.8	628
33	Targeting DNA repair in gliomas. Current Opinion in Neurology, 2019, 32, 878-885.	3.6	11
34	Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model. British Journal of Radiology, 2019, 92, 20180469.	2.2	12
35	Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region. Journal of Magnetic Resonance Imaging, 2019, 50, 529-540.	3.4	13
36	Glioblastoma's Next Top Model: Novel Culture Systems for Brain Cancer Radiotherapy Research. Cancers, 2019, 11, 44.	3.7	59

#	Article	lF	Citations
37	An <sup>18</sup> F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent. Journal of Medicinal Chemistry, 2018, 61, 4103-4114.	6.4	19
38	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 2018, 8, 12-16.	1.7	51
39	SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 2018, 8, 45-49.	1.7	16
40	A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma. Cancer Research, 2018, 78, 6509-6522.	0.9	22
41	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. British Journal of Cancer, 2018, 119, 389-407.	6.4	92
42	Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells. Cancer Research, 2018, 78, 5060-5071.	0.9	118
43	Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open, 2018, 8, e017593.	1.9	40
44	Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma. Frontiers in Immunology, $2018, 9, 1679$ .	4.8	31
45	Multiple boli arterial spin labeling for high signalâ€toâ€noise rodent brain perfusion imaging. Magnetic Resonance in Medicine, 2018, 79, 1020-1030.	3.0	7
46	Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 2018, 5, e000293.	3.0	5
47	A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, 2017, 19, now164.	1.2	75
48	The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. Radiotherapy and Oncology, 2017, 125, 1-12.	0.6	15
49	GBM radiosensitizers: dead in the water…or just the beginning?. Journal of Neuro-Oncology, 2017, 134, 513-521.	2.9	19
50	Improving the Therapeutic Ratio of Radiotherapy by Targeting the DNA Damage Response. Cancer Drug Discovery and Development, 2017, , $1$ -34.	0.4	2
51	Hidden in plain sight: promising therapeutic targets for glioblastoma lurk within DNA damage response pathways. Translational Cancer Research, 2017, 6, S438-S440.	1.0	0
52	The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer. Clinical Oncology, 2016, 28, 720-725.	1.4	6
53	PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. Cancer Research, 2016, 76, 7001-7011.	0.9	41
54	Glioblastoma in the elderly — How do we choose who to treat?. Journal of Geriatric Oncology, 2016, 7, 453-456.	1.0	25

#	Article	IF	Citations
55	Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. BMJ Open, 2016, 6, e013324.	1.9	29
56	Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 2016, 13, 627-642.	27.6	230
57	Science in Focus: Combining Radiotherapy with Inhibitors of the DNA Damage Response. Clinical Oncology, 2016, 28, 279-282.	1.4	14
58	ESTRO-ACROP guideline "target delineation of glioblastomas― Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
59	Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 2016, 7, 22650-22664.	1.8	33
60	Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. Journal of Thoracic Oncology, 2015, 10, 944-950.	1.1	73
61	A novel <sup>18</sup> F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 2015, 6, 4772-4777.	7.4	17
62	Abrogation of radioresistance in glioblastoma stemâ€like cells by inhibition of ATM kinase. Molecular Oncology, 2015, 9, 192-203.	4.6	108
63	Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death. Molecular Cell, 2015, 57, 860-872.	9.7	341
64	Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo. Journal of Medicinal Chemistry, 2015, 58, 8683-8693.	6.4	50
65	Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells. Cancer Research, 2015, 75, 4416-4428.	0.9	154
66	Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 2015, 17, 1556-1568.	10.3	423
67	Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to Irinotecan. Molecular Cancer Therapeutics, 2015, 14, 575-585.	4.1	59
68	Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: Implications for stem cell mitosis and centrosome dynamics. Stem Cell Research, 2014, 13, 135-143.	0.7	43
69	Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Translational Oncology, 2013, 6, 66-74.	3.7	50
70	DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets. Current Medicinal Chemistry, 2012, 19, 3874-3885.	2.4	67
71	Supportive follow-up in patients treated with radical intent for high-grade glioma. CNS Oncology, 2012, 1, 39-48.	3.0	9
72	Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 2012, 14, 392-404.	1,2	166

#	Article	IF	CITATIONS
73	The potential of PARP inhibitors in neuro-oncology. CNS Oncology, 2012, 1, 85-97.	3.0	12
74	Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer, 2012, 106, 18-24.	6.4	91
75	Radioresistance of glioma stem cells: Intrinsic characteristic or property of the â€~microenvironmentâ€stem cell unit'?. Molecular Oncology, 2011, 5, 374-386.	4.6	88
76	A UKâ€wide survey of followâ€up practices for patients with highâ€grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 2011, 17, 1-6.	1.8	11
77	Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets. Seminars in Radiation Oncology, 2010, 20, 274-281.	2.2	123
78	Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair. Molecular Cancer Therapeutics, 2010, 9, 1775-1787.	4.1	118
79	Evaluating novel radiation techniques for the treatment of cerebral metastases. British Journal of Radiology, 2010, 83, 98-100.	2.2	2
80	Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Molecular Cancer Therapeutics, 2009, 8, 2243-2254.	4.1	103
81	Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1188-1197.	0.8	190
82	The potential role and application of PARP inhibitors in cancer treatment. British Medical Bulletin, 2008, 89, 23-40.	6.9	88
83	Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncology, The, 2008, 9, 884-891.	10.7	156
84	Radioresistant glioma stem cells—Therapeutic obstacle or promising target?. DNA Repair, 2007, 6, 1391-1394.	2.8	35
85	An Achilles' heel for breast cancer?. Nature Structural and Molecular Biology, 2005, 12, 387-388.	8.2	4
86	ADVANCES IN MUCOSAL IMMUNOLOGY. Gastroenterology Clinics of North America, 1997, 26, 145-173.	2.2	11
87	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 0, 7, 41251-41264.	1.8	65